TAC新辅助化疗方案对TNBC患者的疗效及TNBC相关免疫组化指标特征分析

The Clinical Efficacy of TAC Neoadjuvant Chemotherapy for Triple Negative Breast Cancer and Related Analysis of Feature of Immunohistochemical Indexes

目的探究TAC新辅助化疗方案对TNBC患者的疗效及TNBC相关免疫组化指标特征分析。方法回顾性分析我科收治的80例女性乳腺癌患者的临床资料,均采用TAC新辅助化疗方案,分为TNBC患者(研究组)和非TNBC患者(对照组),观察两组的治疗效果等差异。结果新辅助治疗前两组患者的穿刺免疫组化相关指标表达情况比较发现研究组中CK5/6及EGFR阳性率显著高于对照组,而E-cadhenrin的表达率低于对照组(P <0.05);新辅助化疗后研究组的完全缓解率(CR)和病理完全缓解率(pCR)均显著高于对照组(P <0.05);两组患者新辅助化疗后的毒副反应发生率比较无统计学差异(P>0. 05);与治疗前比较,两组患者的OPN及VEGF-C水平均降低(P <0. 05);而与对照组比较,研究组患者的OPN及VEGF-C水平均更低(P<0.05)。结论 TAC新辅助化疗方案对于TNBC患者疗效显著,同时其不增加副反应发生率,并可有效提高患者的预后。

Objective To investigate the clinical efficacy of TAC Neoadjuvant chemotherapy for triple negative breast cancer and analyze the related feature of immunohistochemical indexes. Methods 80 patients with BC were divided into the TNBC group and non-TNBC group, each with 40 cases, then the two groups were compared in terms of clinical efficacy and related items. Results The expressions of CK5/6 and EGFR in study group were higher than the control group （P 〈 0.05 ） ; The clinical efficacy in study group was higher than the control group （ P 〈 0.05 ） ; There was no significant difference in postoperative complications between 2 groups （P 〉 0.05 ） ; The serum prognosis indexes were all lower in study group than in the control group after the treatment （ P 〈 0.05. Conclusion The TAC Neoadjuvant chemotherapy for triple negative breast cancer has significant effects and it is worthy of clinical application